Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with Rebif® New Formulation (REFLEXION)

Trial Profile

Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with Rebif® New Formulation (REFLEXION)

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms REFLEXION
  • Sponsors Merck KGaA; Merck Serono
  • Most Recent Events

    • 28 Oct 2017 Results of post hoc analysis of REFLEX and REFLEXION trials assessing the impact of gadolinium-enhancing (Gd+) lesions at baseline on NEDA presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Apr 2017 Results of post-hoc analysis conducted in the intent-to-treat population of this and REFLEX trial presented at the 69th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2017 Data from this trial will be presented at the American Academy of Neurology (AAN) 69th Annual Meeting, as reported in an EMD Serono media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top